Compound ID | 2882
AP-PA02
Class: Bacteriophage and/or bacteriophage-derived product
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Pseudomonas aeruginosa |
| Description: | A phage cocktail from Pseudomonas aeruginosa; phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients delivered via inhalation |
| Institute where first reported: | Armata Pharmaceuticals |
| Year first mentioned: | 2023 |
| Highest developmental phase: | Phase 2 (NCT05616221) |
| Development status: | Active as of 2024 |
| External links: | |
| Citation: | https://www.armatapharma.com/pipeline/ap-pa02/ |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.